Persistent Remnants of Dexamethasone Intravitreal Implant Over 24 Months in a Patient Suffering from Anterior and Intermediate Uveitis Associated with Macular Edema

Giorgio Enrico Bravetti; Jean Vaudaux; Jean-Antoine Pournaras; Aude Ambresin

doi:10.1055/a-1384-1056

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2021; 238(04): 454-457
DOI: 10.1055/a-1384-1056

Der interessante Fall

Persistent Remnants of Dexamethasone Intravitreal Implant Over 24 Months in a Patient Suffering from Anterior and Intermediate Uveitis Associated with Macular Edema

Persistente Reste des intravitrealen Dexamethason-Implantats nach 24 Monaten bei einem Patienten mit Vorder- und Mittelstufe einer Uveitis, im Zusammenhang mit einem Makulaödem

Giorgio Enrico Bravetti

¹Retina Department, Ophthalmology Center, RétinElysée, Lausanne, Switzerland, Lausanne, Switzerland

,

Jean Vaudaux

¹Retina Department, Ophthalmology Center, RétinElysée, Lausanne, Switzerland, Lausanne, Switzerland

²Ophthalmology, Private practice, Morges, Switzerland

,

Jean-Antoine Pournaras

¹Retina Department, Ophthalmology Center, RétinElysée, Lausanne, Switzerland, Lausanne, Switzerland

,

Aude Ambresin

¹Retina Department, Ophthalmology Center, RétinElysée, Lausanne, Switzerland, Lausanne, Switzerland

³Opthalmology Departement, Swiss Visio, Clinique de Montchoisi, Lausanne, Switzerland, Lausanne, Switzerland

› Author Affiliations

Abstract

Full Text

References

References
1 Yoon YH, Boyer DS, Maturi RK. et al. Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study). Graefes Arch Clin Exp Ophthalmol 2019; 257: 2639-2653 doi:10.1007/s00417-019-04464-2
2 Haller JA, Bandello F, Belfort jr. R. et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.e3 doi:10.1016/j.ophtha.2010.03.032
3 Longo A, Reibaldi M, Uva MG. et al. Acute serous macular detachment and edema after uncomplicated phacoemulsification: A case series. Can J Ophthalmol 2015; 50: 476-479 doi:10.1016/j.jcjo.2015.08.005
4 Russo A, Avitabile T, Uva M. et al. Radiation Macular Edema after Ru-106 Plaque Brachytherapy for Choroidal Melanoma Resolved by an Intravitreal Dexamethasone 0.7-mg Implant. Case Rep Ophthalmol 2012; 3: 71-76 doi:10.1159/000337144
5 Ceravolo I, Oliverio GW, Alibrandi A. et al. The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema. Diagnostics (Basel) 2020; 10: 413 doi:10.3390/diagnostics10060413
6 Augustin AJ, Kuppermann BD, Lanzetta P. et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 2015; 15: 150 doi:10.1186/s12886-015-0148-2
7 Boyer DS, Yoon YH, Belfort jr. R. et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914 doi:10.1016/j.ophtha.2014.04.024
8 Haller JA, Bandello F, Belfort jr. R. et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460 doi:10.1016/j.ophtha.2011.05.014
9 Yalcinbayir O, Caliskan E. Ucan Gunduz G et al. Efficacy of Dexamethasone Implants in Uveitic Macular Edema in Cases with Behçet Disease. Ophthalmologica 2019; 241: 190-194 doi:10.1159/000490674
10 Lowder C, Belfort jr. R, Lightman S. et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553 doi:10.1001/archophthalmol.2010.339
11 U.S. Food and Drug Administration (FDA). Drug Approval Package. Ozurdex (dexamethasone intravitreal implant). Accessed March 29, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022315_ozurdex_toc.cfm
12 Chang-Lin JE, Attar M, Acheampong AA. et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52: 80-86 doi:10.1167/iovs.10-5285
13 Lightman S, Belfort jr. R, Naik RK. et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci 2013; 54: 4864-4870 doi:10.1167/iovs.12-10981
14 Mazzarella S, Mateo C, Freixes S. et al. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex^®) on intraocular pressure in patients with macular edema. Ophthalmic Res 2015; 54: 143-149 doi:10.1159/000438759
15 Maturi RK, Pollack A, Uy HS. et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 2016; 36: 1143-1152 doi:10.1097/iae.0000000000001004
16 Kim JT, Lee SH, Choi SU. Persistent remnants of dexamethasone intravitreal implant (Ozurdex). Retina 2020; 40: 2226-2231 doi:10.1097/iae.0000000000002778
17 Gillies MC, Simpson JM, Gaston C. et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009; 116: 2182-2187 doi:10.1016/j.ophtha.2009.04.049
18 Ip MS, Gottlieb JL, Kahana A. et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004; 122: 1131-1136 doi:10.1001/archopht.122.8.1131
19 Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111: 2044-2049 doi:10.1016/j.ophtha.2004.05.025
20 Sarraf D, Vyas N, Jain A. et al. Triamcinolone-associated crystalline maculopathy. Arch Ophthalmol 2010; 128: 685-690 doi:10.1001/archophthalmol.2010.109
21 Zarifa R, Shaikh S, Kester E. Peristence of triamcinolone crystals after intra-vitreal injection: benign crystalline hyaloidopathy. Indian J Ophthalmol 2013; 61: 182-183 doi:10.4103/0301-4738.112166
22 Lee SS, Hughes P, Ross AD. et al. Biodegradable implants for sustained drug release in the eye. Pharm Res 2010; 27: 2043-2053 doi:10.1007/s11095-010-0159-x
23 Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) 2011; 3: 1377-1397 doi:10.3390/polym3031377
24 Yasukawa T, Ogura Y, Kimura H. et al. Drug delivery from ocular implants. Expert Opin Drug Deliv 2006; 3: 261-273 doi:10.1517/17425247.3.2.261
25 Reibaldi M, Russo A, Zagari M. et al. Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg. Case Rep Ophthalmol 2012; 3: 30-34 doi:10.1159/000336273
26 Boyer DS, Faber D, Gupta S. et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915-923 doi:10.1097/IAE.0b013e318206d18c